Navigation Links
Digital Healthcare Announces Appointment of Dr. Suber Huang as Medical Director
Date:11/15/2007

Suber S. Huang, MD, MBA, will serve as Digital's Medical Director for

Ophthalmology

WAKE FOREST, N.C., Nov. 15 /PRNewswire/ -- Digital Healthcare, a Wake Forest, NC company specializing in retinal risk assessment for diabetics, announced today that Suber S. Huang, MD, MBA has been named Medical Director for Ophthalmology. Dr. Huang will provide the company expert advice and counsel regarding product development and development.

Dr. Huang is the Philip F. and Elizabeth G. Searle-Suber Huang, MD, Professor and Vice Chairman in the Department of Ophthalmology and Visual Sciences, University Hospitals Case Medical Center, Cleveland, Ohio. He is the Director of Vitreoretinal Diseases and Surgery, the Director of Clinical Research, and the Director of the Retinal Diseases Image Analysis Reading Center (REDIARC). Dr. Huang serves on the Executive Board of Directors for the American Society of Retina Specialists, the world's largest organization of retinal specialists. Dr. Huang is the Director of the Diabetic Eye Disease Committee of the National Eye Health Education Program and the serves on the Ophthalmic Technology Assessment Committee (OTAC)-Retina/Vitreous Panel and on the Research, Regulatory, and External Scientific Relations Committee, both committees associated with the American Academy of Ophthalmology.

"Having one of the country's premier retinal specialists on our team will be invaluable," said Marc Winchester, President, North America and Board Director of Digital Healthcare. "Retasure is focused on retinal health and, we will rely on Dr. Huang's vast medical expertise to advise us on future product enhancements. With Dr. Huang's input, Retasure will continue to be the industry's leading retinal risk assessment tool."

"Retasure is a terrific system that provides benefits for patients at risk for diabetic retinopathy," said Dr. Huang. "Earlier detection of patients with diabetic eye disease by endo
'/>"/>

SOURCE Digital Healthcare Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Digital Healthcare Wins FDA Approval for Retasure
2. Digital Healthcare Wins FDA Approval for Retasure
3. Astra Tech Acquires Innovative Dental Digital Technology Company
4. Digital Info Security Company and DGF MedServ, Inc. Announce Intent to Partner in Marketing DGIF IT Solutions to Medical Industry
5. Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy
6. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
7. Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S.
8. SMRT Architects and Engineers Selected to Design New $115M Digital X-Ray Manufacturing Facility for GE Healthcare
9. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Negative Pressure Wound Devices Draw FDA Notice, Advice 2Hangovers May Be Tougher for Migraine Sufferers 59737 1Drugs for Irritable Bowel Might Increase Cancer Risk 59736 1Drugs for Irritable Bowel Might Increase Cancer Risk 59736 2Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 1Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 2Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 3